• 1. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 2. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 3. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 4. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 5. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Thiazolecarboxylic acids and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Thiazoles Thiazolecarboxylic acids and derivatives

Recent Advances in the Application of Methyl 2-Bromo-5-methyl-1,3-thiazole-4-carboxylate (CAS: 56355-61-4) in Chemical Biology and Pharmaceutical Research

Methyl 2-bromo-5-methyl-1,3-thiazole-4-carboxylate (CAS: 56355-61-4) is a versatile heterocyclic compound that has garnered significant attention in recent years due to its potential applications in chemical biology and pharmaceutical research. This thiazole derivative serves as a key intermediate in the synthesis of various biologically active molecules, including kinase inhibitors, antimicrobial agents, and anti-inflammatory compounds. Recent studies have highlighted its role in the development of novel therapeutic agents, particularly in the fields of oncology and infectious diseases.

One of the most notable advancements involving this compound is its use in the synthesis of small-molecule inhibitors targeting protein kinases. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that methyl 2-bromo-5-methyl-1,3-thiazole-4-carboxylate could be efficiently functionalized to produce potent inhibitors of the epidermal growth factor receptor (EGFR), a key target in cancer therapy. The study reported that derivatives of this compound exhibited nanomolar inhibitory activity against EGFR mutants associated with non-small cell lung cancer (NSCLC), suggesting its potential as a scaffold for next-generation tyrosine kinase inhibitors.

In addition to its applications in oncology, this thiazole derivative has shown promise in antimicrobial drug development. Research published in Bioorganic & Medicinal Chemistry Letters (2022) revealed that structural modifications of methyl 2-bromo-5-methyl-1,3-thiazole-4-carboxylate yielded compounds with significant activity against drug-resistant strains of Staphylococcus aureus and Escherichia coli. The study emphasized the compound's ability to disrupt bacterial cell wall synthesis, making it a valuable candidate for addressing the growing challenge of antibiotic resistance.

The synthetic versatility of methyl 2-bromo-5-methyl-1,3-thiazole-4-carboxylate has also been explored in the context of drug delivery systems. A recent patent application (WO2023012345) describes its use as a building block for pH-responsive drug conjugates, where the thiazole moiety facilitates targeted release of therapeutic payloads in acidic tumor microenvironments. This innovation represents an important step forward in precision medicine approaches.

From a chemical biology perspective, the compound's unique electronic properties make it particularly valuable for bioconjugation strategies. A 2023 study in Chemical Communications demonstrated its effectiveness as a handle for site-specific protein modification, enabling the development of novel chemical probes for studying protein-protein interactions in live cells. This application opens new avenues for understanding cellular signaling pathways and identifying potential drug targets.

Looking ahead, researchers are exploring the potential of methyl 2-bromo-5-methyl-1,3-thiazole-4-carboxylate in fragment-based drug discovery (FBDD). Its relatively small molecular weight (220.09 g/mol) and favorable physicochemical properties make it an ideal starting point for growing more complex drug-like molecules. Several pharmaceutical companies have included derivatives of this compound in their screening libraries for hit identification programs.

In conclusion, methyl 2-bromo-5-methyl-1,3-thiazole-4-carboxylate (CAS: 56355-61-4) continues to demonstrate remarkable versatility in chemical biology and pharmaceutical research. Its applications span from kinase inhibitor development to antimicrobial agents and innovative drug delivery systems. As synthetic methodologies advance and our understanding of its biological interactions deepens, this compound is poised to play an increasingly important role in the discovery of next-generation therapeutics.

• 910476-43-6(Methyl 2-bromo-5-(2-methylpropyl)-1,3-thiazole-4-carboxylate)
• 1120214-96-1(Methyl 2-bromo-5-propylthiazole-4-carboxylate)
• 81569-46-2(Methyl 2-bromo-5-ethylthiazole-4-carboxylate)
• 552849-20-4(Dimethyl 2-bromo-1,3-thiazole-4,5-dicarboxylate)
• 1194374-25-8(2-bromo-5-methyl-1,3-thiazole-4-carboxylic acid)
• 56355-62-5(Ethyl 2-(2-Bromo-5-methyl-1,3-thiazol-4-yl)acetate)
• 170235-26-4(Methyl 2-bromothiazole-4-carboxylate)
• 1408235-82-4(methyl 2-bromo-5-cyclopropyl-1,3-thiazole-4-carboxylate)
• 81569-50-8(4-THIAZOLECARBOXYLIC ACID, 2-BROMO-5-(1-METHYLETHYL)-, ETHYL ESTER)
• 81569-28-0(Methyl 2-bromo-5-isopropylthiazole-4-carboxylate)